Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18509218 | 0.89 | HPGD (0.49) | SMN1; SMN2HPGDALDH1A1LMNANPC1 | |
| SCHEMBL14614571 | 0.89 | CYP3A4 (0.53) | SMN1; SMN2HPGDALDH1A1LMNANPC1 | |
| SCHEMBL14614695 | 0.86 | NPC1 (0.52) | SMN1; SMN2HPGDALDH1A1LMNANPC1 | |
| SCHEMBL14924073 | 0.86 | KDM2B (0.48) | SMN1; SMN2HPGDALDH1A1LMNANPC1 | |
| SCHEMBL12160700 | 0.84 | ALDH1A1 (0.53) | SMN1; SMN2HPGDALDH1A1NPC1TSHR | |
| SCHEMBL23279482 | 0.84 | NPC1 (0.56) | SMN1; SMN2HPGDALDH1A1LMNANPC1 | |
| SCHEMBL22296418 | 0.83 | MAPT (0.58) | SMN1; SMN2ALDH1A1LMNANPC1ALOX15 | |
| SCHEMBL14200387 | 0.83 | NPC1 (0.44) | SMN1; SMN2HPGDALDH1A1LMNANPC1 | |
| SCHEMBL13450397 | 0.83 | ALDH1A1 (0.48) | SMN1; SMN2HPGDALDH1A1LMNANPC1 | |
| SCHEMBL20457963 | 0.83 | HPGD (0.39) | SMN1; SMN2HPGDALDH1A1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100152186-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7718683-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7683176-B2 | Triazolyl pyridyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683176-B2 | Triazolyl pyridyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | SMN1; SMN2 4113/4885HPGD 2329/4885ALDH1A1 2924/4885 |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | SMN1; SMN2 2420/4885HPGD 2868/4885ALDH1A1 2935/4885 |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | SMN1; SMN2 2093/4885HPGD 2056/4885ALDH1A1 2696/4885 |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | ENPP2, ROCK2, RRP12 | SMN1; SMN2 4183/4885HPGD 3124/4885ALDH1A1 3183/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | SMN1; SMN2 2917/4885HPGD 556/4885ALDH1A1 2992/4885 |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | SMN1; SMN2 3671/4885HPGD 1412/4885ALDH1A1 4227/4885 |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | SMN1; SMN2 3707/4885HPGD 1845/4885ALDH1A1 2446/4885 |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | SMN1; SMN2 3671/4885HPGD 1412/4885ALDH1A1 4227/4885 |
| US-20100152186-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | SMN1; SMN2 2093/4885HPGD 2056/4885ALDH1A1 2696/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | SMN1; SMN2 4599/4885HPGD 2700/4885ALDH1A1 2890/4885 |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | SMN1; SMN2 2420/4885HPGD 2868/4885ALDH1A1 2935/4885 |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | SMN1; SMN2 3671/4885HPGD 1412/4885ALDH1A1 4227/4885 |
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | ACE, SARS1, ACE2 | SMN1; SMN2 890/4885HPGD 3583/4885ALDH1A1 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.